Patent · US Active

Ganirelix precursor and method for preparing ganirelix acetate by using the same

US10577394B2 · kind B2 · utility

0Cited by

2References

20Claims

0Family size

Assignee

Hybio Pharmaceutical Co., Ltd. · CN

Inventors

Youjin Chen · Nanhu, CN
Jian Liu · Zhejiang, CN
Yaping Ma · Nanhu, CN
Jiancheng Yuan · Nanhu, CN

Key dates

Filing date	Jun 12, 2015
Grant date	Mar 3, 2020
Priority date	—
Expiry date	Jan 14, 2036

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02P20/55
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Disclosed is a method for preparing ganirelix acetate. The method includes the following steps: respectively replacing Fmoc-HArg(Et)2-OH and Fmoc-D-HArg(Et)2-OH by employing Fmoc-Lys(Boc)-OH and Fmoc-D-Lys(Boc)-OH or Fmoc-Lys(Alloc)-OH and Fmoc-D-Lys(Alloc)-OH; synthesizing a ganirelix precursor I or ganirelix precursor II-peptide resin in advance; and then respectively performing modifications and treatments on side chain amino groups of Lys and D-Lys in the precursor I or the precursor II-peptide resin to obtain ganirelix acetate. The ganirelix acetate synthesized therefrom is high in purity, has few impurities and a relatively low cost, and is suitable for large-scale production.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.